Soleno Therapeutics Inc Stock Price, News & Analysis

Soleno Therapeutics (NASDAQ: SLNO) entered an $100 million Accelerated Share Repurchase (ASR) with Jefferies on Nov 11, 2025, with an initial payment of $100 million and an initial delivery of ~1,511,553 shares based on the Nov 10, 2025 close. The final repurchased share count will be adjusted by the volume-weighted average price during the ASR term. The company said the ASR supports confidence after achieving profitability in Q3 2025. The ASR is expected to complete in Q1 2026.

Soleno Therapeutics (NASDAQ: SLNO) reported third quarter 2025 results and a U.S. launch update for VYKAT XR on November 4, 2025. Key highlights: Q3 product revenue $66.0M, net income $26.0M for the quarter, and $556.1M in cash, cash equivalents and marketable securities as of September 30, 2025 (includes $230M gross proceeds raised in July). From FDA approval on March 26, 2025 through Sept 30, 2025: 1,043 patient start forms, 764 active patients, and 494 unique prescribers. Q3 product revenue rose >100% sequentially vs Q2. Company noted contingent consideration fair value of $19.5M tied to commercial milestones.

Soleno Therapeutics (NASDAQ: SLNO) announced participation in three investor conferences in November 2025 with dates, times, formats, and webcast availability.

Events: Guggenheim Securities Healthcare Innovation Conference on Nov 11, 2025 at 9:00 AM ET (fireside chat); Stifel 2025 Healthcare Conference on Nov 12, 2025 at 8:40 AM ET (fireside chat); and Jefferies London Healthcare Conference on Nov 18, 2025 at 5:00 PM GMT (presentation). Replays will be posted in the investor section at www.soleno.life.

Soleno Therapeutics (NASDAQ: SLNO) will report third quarter 2025 financial results and operational highlights after the U.S. market close on Tuesday, November 4, 2025.

The company will host a live conference call and webcast at 4:30 PM Eastern Time on that date. Dial-in numbers are 1-800-717-1738 (U.S.) and 1-646-307-1865 (international) with Conference ID 48794. A webcast will be available on the company website and replayable for 30 days.

Soleno Therapeutics (NASDAQ: SLNO) announced the appointment of biopharmaceutical finance executive Mark W. Hahn to its Board of Directors and as a member of its Audit Committee, increasing the Board to seven members.

Mr. Hahn brings nearly 30 years of CFO-level experience across life sciences companies, including roles that covered product launches, financings and M&A. His background includes serving as CFO of Verona Pharma through its phase 3 program and launch and its acquisition by Merck for approximately $10 billion (Oct 2025), and as CFO of Dova Pharmaceuticals through its sale for up to $915 million (Nov 2019). Soleno noted the hire aligns with its ongoing commercial launch of VYKAT™ XR and named Mr. Hahn as Audit Committee member.

Soleno Therapeutics (NASDAQ: SLNO), a biopharmaceutical company focused on rare disease therapeutics, has announced its participation in five major healthcare investor conferences during September 2025.

The company will present at the Cantor Global Healthcare Conference (Sept 3), Wells Fargo Healthcare Conference (Sept 4), H.C. Wainwright Global Investment Conference (Sept 8), Baird Global Healthcare Conference (Sept 9), and Bernstein Healthcare Forum (Sept 25). All presentations will be in fireside chat format.

Webcasts for the Cantor and Wells Fargo events will be available for replay on Soleno's website.

Soleno Therapeutics (NASDAQ:SLNO) reported significant progress in Q2 2025, highlighted by the successful launch of VYKAT XR, the first FDA-approved therapy for Prader-Willi Syndrome (PWS). Since its April 14 launch, the company has received 646 patient start forms from 295 unique prescribers, with coverage extending to over 100 million lives.

The company reported Q2 2025 product revenue of $32.7 million and ended the quarter with $293.8 million in cash and equivalents. Additionally, Soleno raised $230 million through a stock offering in July. The company's Marketing Authorization Application (MAA) for VYKAT XR has been submitted to the European Medicines Agency (EMA) for PWS treatment approval in the EU.

Soleno Therapeutics (NASDAQ: SLNO), a biopharmaceutical company focused on rare diseases, has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after market close. The company will host a conference call and webcast at 4:30 PM ET to discuss results and provide business updates.

The press release also includes important safety information for VYKAT XR, their treatment for hyperphagia in Prader-Willi syndrome (PWS) patients aged 4 and older. Key safety considerations include monitoring for hyperglycemia and fluid overload, with the most common adverse reactions being hypertrichosis, edema, hyperglycemia, and rash.

Soleno Therapeutics (NASDAQ: SLNO) has announced the pricing of its public offering of 2,352,941 shares of common stock at $85.00 per share, aiming to raise approximately $200 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase up to 352,941 additional shares.

The proceeds will primarily fund the commercialization of VYKATT™ XR, their recently FDA-approved therapy for hyperphagia in Prader-Willi syndrome patients. Additional funds will support EU regulatory activities, research and development, and general corporate purposes. The offering, managed by Goldman Sachs, Guggenheim Securities, TD Cowen, Cantor, and Oppenheimer, is expected to close around July 11, 2025.